Ipsen

Ipsen, a French-headquartered company in Pharmaceutical Preparation Manufacturing, reported total emissions of approximately 111,217 metric tons CO2e in 2024. This includes 9,932 metric tons CO2e from Scope 1 emissions, 289 metric tons CO2e from market-based Scope 2 emissions, and 90,705 metric tons CO2e from Scope 3 emissions.

Ipsen has set several ambitious climate commitments:

• Near-Term Targets (SBTi): Ipsen commits to reduce absolute Scope 1 and 2 GHG emissions by 57% by 2030 from a 2019 base year. Additionally, they aim to reduce absolute Scope 3 GHG emissions by 28% within the same timeframe. These targets are consistent with reductions required to limit global warming to 1.5°C.
• Long-Term/Net-Zero Targets (SBTi): Ipsen is committed to achieving net-zero greenhouse gas emissions across its entire value chain by 2045. This involves reducing absolute Scope 1, 2, and 3 GHG emissions by 90% by 2045 from a 2019 base year, in line with the SBTi's Corporate Net-Zero Standard.

The company's decarbonisation roadmap is designed to support these targets.

Looking back, Ipsen's emissions were approximately:

• 2023: 11,516 metric tons CO2e (Scope 1) and 367 metric tons CO2e (market-based Scope 2). Scope 3 data was not provided for this year.
• 2022: 11,920 metric tons CO2e (Scope 1), 1,567 metric tons CO2e (market-based Scope 2), and 17,956 metric tons CO2e (Scope 3).
• 2021: 11,477 metric tons CO2e (Scope 1), 2,497 metric tons CO2e (market-based Scope 2), and 11,268 metric tons CO2e (Scope 3).
• 2019: 14,316 metric tons CO2e (Scope 1), 4,343 metric tons CO2e (market-based Scope 2), and 121,718 metric tons CO2e (Scope 3).